# A Trial of TTA-121 on Autism Spectrum Disorder

> **NCT03466671** · PHASE2 · UNKNOWN · sponsor: **Hamamatsu University** · enrollment: 144 (estimated)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** TTA-121

## Key facts

- **NCT ID:** NCT03466671
- **Lead sponsor:** Hamamatsu University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-27
- **Primary completion:** 2020-03-16
- **Final completion:** 2020-03-30
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2019-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03466671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03466671, "A Trial of TTA-121 on Autism Spectrum Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03466671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*